Circio Holding ASA
OSE:CRNA
Circio Holding ASA
Circio Holding ASA is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company is headquartered in Lysaker, Akershus and currently employs 21 full-time employees. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
Circio Holding ASA is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. The company is headquartered in Lysaker, Akershus and currently employs 21 full-time employees. The company went IPO on 2014-06-16. The firm is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The firm offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circio’s second clinical program is an immunotherapy targeting KRAS driver mutations.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
